Evidence map›Paper›PMID 31921170›Full record

ArticleFrontiers in immunology2019

The Safety and Immunogenicity of GTU

G Haidari, Suzanne Day, M Wood, H Ridgers, Alethea V Cope, Sue Fleck, Celine Yan, Kalevi Reijonen, Drew Hannaman, Aggeliki Spentzou and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Vaccines for COVID-19.Clinical and experimental immunology · 2020
    Review
  5. Article
  6. Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 5 countries.

G HaidariGroup of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom.
Suzanne DayGroup of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom.
M WoodGroup of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom.
H RidgersGroup of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom.
Alethea V CopeGroup of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom.
Sue FleckLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Celine YanGroup of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom.
Kalevi ReijonenFIT Biotech Ltd., Tampere, Finland.
Drew HannamanIchor Medical Systems Inc, San Diego, CA, United States.
Aggeliki SpentzouGroup of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom.
Peter HayesHuman Immunology Laboratory, International AIDS Vaccine Initiative, Imperial College London, London, United Kingdom.
A VogtDepartment of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Behazine CombadiereSorbonne Université, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), INSERM U1135, Paris, France.
Adrian CookMedical Research Council Clinical Trials Unit at UCL, University College London, London, United Kingdom.
Sheena McCormackMedical Research Council Clinical Trials Unit at UCL, University College London, London, United Kingdom.
Robin J ShattockGroup of Mucosal Infection and Immunity, Department of Medicine, Imperial College London, London, United Kingdom.
Imperial College London · GBCentre d'Immunologie et des Maladies Infectieuses · FRClinical Research Center for Hair and Skin Science · DEFIT Biotech (Finland) · FIIchor Medical Systems (United States) · USLondon School of Hygiene & Tropical Medicine · GBMRC Clinical Trials Unit at UCL · GBUniversity College London · GB

Funding

Medical Research Council MC_U122861400Medical Research Council MC_UU_12023/23
6 · The paper itself

Abstract

Previous studies have shown targeting different tissues via the transcutaneous (TC) and intramuscular injection (IM) with or without electroporation (EP) has the potential to trigger immune responses to DNA vaccination. The CUTHIVTHER 001 Phase I/II randomized controlled clinical trial was designed to determine whether the mode of DNA vaccination delivery (TC+IM or EP+IM) could influence the quality and function of induced cellular immune responses compared to placebo, in an HIV positive clade B cohort on antiretroviral therapy (ART). The GTU

Indexed as

Immunogenicity, VaccineAdministration, CutaneousAIDS VaccinesAntiretroviral Therapy, Highly ActiveCytokinesElectroporationHIV-1HIV InfectionsHumansInjections, IntramuscularPatient Outcome AssessmentVaccinationVaccines, DNAAIDS VaccinesCytokinesVaccines, DNAelectroporationHIV-1plasmid DNAtherapeutic vaccinetranscutaneous

Identifiers

PMID31921170
PMCPMC6923267
OpenAlexW2991003338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.